Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Freshworks Inc (FRSH) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Freshworks IncTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Freshworks Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Freshworks Inc trades at $11.96 (market cap $3.31B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 25.1× Freshworks Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals.

FRSHREGN
Market Cap
$3.31B$83.19B
Sector
TechnologyHealth
52-Week High
$13.97$812.27
52-Week Low
$6.88$555.51
Enterprise Value
$2.68B$77.90B
Dividend Yield
0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Freshworks Inc

Freshworks (FRSH) trades at $11.84, up 2.16% today, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $0.17 versus $0.13 expected, and revenue growth of 16% year-over-year. Recent developments include FedRAMP 'In-Process' status for Freshservice and a leadership appointment, reinforcing its competitive position in AI-powered service operations.

The stock offers upside to the $16.50 consensus price target, driven by robust fundamentals like a 20.49% net margin and 19.7% ROE. Risks include high EV/EBITDA valuation and dependence on SaaS sector growth. Analysts are evenly split between Buy and Hold ratings, indicating cautious optimism amid execution risks.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Freshworks Inc

Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.

Read more on FRSH

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN